Shoshana Sztal-Mazer

Shoshana Sztal-Mazer

Auto-generated profile, based on publicly available information

Shoshana Sztal-Mazer

Department of Endocrinology and Diabetes, Alfred Health , 3004, VIC

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in Clinical Endocrinology
Verified
Journal Article
Open access
PDF file
CAClaudia Ashkar
Claudia Ashkar
SSShoshana Sztal‐Mazer
Shoshana Sztal‐Mazer
DTDuncan K Topliss
Duncan K Topliss
The management of Graves’ disease (GD) in women of childbearing potential has multiple specific complexities. Many factors are involved, which differ at the various stages from preconception, conception, first trimester, later pregnancy, postpartum and lactation, with both maternal and foetal considerations. The incidence and significance of the risks incurred from antithyroid drugs (ATDs) in pregnancy have been re‐evaluated recently and must be balanced against the risks of uncontrolled hyperthyroidism during childbearing years. Contraception is advised until hyperthyroidism is controlled. ATD cessation should be considered in those who are well controlled on low dose therapy before conception and in early pregnancy. Advice on iodine supplementation does not generally differ in those with GD. Radioiodine (RAI) is contraindicated from 6 months preconception until completion of breastfeeding. In all women who have a history of GD, monitoring of TSH receptor antibodies (TRAb) is strongly recommended during pregnancy, and if elevated, foetal monitoring and assessment of thyroid function in the neonate are required. Of note, RAI increases TRAb for up to a year, making this treatment option even less attractive in this patient group. A small amount of ATD is transferred into breast milk but low doses are safe during lactation. Routine periodic thyroid function testing is recommended in remission to detect postpartum GD recurrence. We present our approach to the Clinical Question ‘How to manage GD in women of childbearing potential?’

25 April 2021 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
PHPeter S Hamblin
Peter S Hamblin
RWRosemary Wong
Rosemary Wong
EEElif.I. Ekinci
Elif.I. Ekinci
SSShoshana Sztal-Mazer
Shoshana Sztal-Mazer
SBShananthan Balachandran
Shananthan Balachandran
LBLeon Bach
Leon Bach

1 October 2021 in Journal of Clinical Densitometry
Verified
Journal Article
Closed access
ENElisabeth Ng
Elisabeth Ng
DTDuncan K Topliss
Duncan K Topliss
MPMiranda Paraskeva
Miranda Paraskeva
EPEldho Paul
Eldho Paul
SSShoshana Sztal-Mazer
Shoshana Sztal-Mazer

28 December 2021 in Diabetes Care
Verified
Journal Article
Open access
PDF file
PHPeter S Hamblin
Peter S Hamblin
RWRosemary Wong
Rosemary Wong
EEElif.I. Ekinci
Elif.I. Ekinci
SSShoshana Sztal-Mazer
Shoshana Sztal-Mazer
SBShananthan Balachandran
Shananthan Balachandran
LBLeon Bach
Leon Bach
We thank Dr. Thiruvenkatarajan et al. (1) for their interest in our article (2). In developing the reference interval for blood ketone concentrations, we used t

26 October 2021 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
PHPeter S Hamblin
Peter S Hamblin
RWRosemary Wong
Rosemary Wong
EEElif.I. Ekinci
Elif.I. Ekinci
SSShoshana Sztal‐Mazer
Shoshana Sztal‐Mazer
SBShananthan Balachandran
Shananthan Balachandran
LBLeon Bach
Leon Bach

16 April 2026 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
LCLucy Collins
Lucy Collins
CSCat Shore-Lorenti
Cat Shore-Lorenti
CCColin Chen
Colin Chen
FMFrances Milat
Frances Milat
SSShoshana Sztal-Mazer
Shoshana Sztal-Mazer
HNHanh H Nguyen
Hanh H Nguyen
Osteoporosis prevalence is expected to increase with global aging. Bisphosphonates and denosumab are effective treatments, but anxiety regarding safety concerns, medication-related osteonecrosis of the jaw and atypical femur fractures (AFFs), have contributed to a decline in bisphosphonate use in recent years. The Transcontinental Atypical Femoral Fracture Consortium (TrAFFiC) was established to identify potential higher risk clinical factors contributing to AFF development. Within TrAFFiC, an AFF registry was established. One hundred and sixty-six patients with AFFs were included. Seventy-seven (46%) patients sustained bilateral AFFs, totaling 243 AFFs (138 complete and 105 incomplete). Sixty-two (37%) individuals were of Asian ethnicity, with 40 (24%) specifically of Southeast Asian ethnicity. Comparisons within this AFF cohort revealed that Asian individuals were shorter and lower weight (152.0 cm vs 154.6 cm, p < .038; 57.5 kg vs 66.8 kg, p < .001) than non-Asian peers and were less likely to have a history of minimal trauma fractures prior to AFF (53% vs 84%, p < .001). Asian ethnicity [OR 2.10 (95% CI 1.06, 4.02), p = .034] and Southeast Asian ethnicity [OR 3.25 (95% CI 1.55, 6.8), p = .002] were associated with an increased likelihood of “earlier onset” AFF development, that is, an AFF sustained following ≤5 yr of antiresorptive treatment. Lastly, teriparatide use following incomplete AFF (n = 34) did not affect time to healing or pain resolution. In conclusion, Asian individuals sustained AFFs following a shorter duration of antiresorptive treatment compared with non-Asian AFF peers. In addition, Asian individuals were less likely to sustain additional minimal trauma fractures. While assessment for a drug holiday may be appropriate for patients at lower risk of AFF after 5 yr of oral antiresorptive treatment, in those with risk factors for “earlier onset” AFF, further research is required to guide whether a lower dose or shorter duration of treatment or prioritization of bone anabolic treatments should be considered.